Progress in human ovarian tissue cryopreservation and transplantation

doi:10.3969/j.issn.1006-7795.2017.04.001

Abstract

Abstract: The survival rate of cancer patients is increasing with the development of cancer treatment methods. However, gonadotoxic therapies have an irreversible impact on ovarian function. Effective fertility protection and improving the level of reproductive health have become a crucial problem that health care providers confront. Improvements of oocyte and embryo cryopreservation, and ovarian tissue cryopreservation and transplantation provide feasible options for women's fertility protection. This review discusses the common fertility protection methods, focusing on the important role of human ovarian tissue cryopreservation and transplantation for fertility protection.

Key words: gonadotoxicity therapy, fertility protection, ovarian tissue cryopreservation and transplantation, oocyte cryopreservation, embryo cryopreservation

CLC Number:

R711.75

Li Yanglu, Ruan Xiangyan, Alfred O. Mueck. Progress in human ovarian tissue cryopreservation and transplantation[J]. Journal of Capital Medical University, 2017, 38(4): 485-491.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.04.001

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I4/485

References

[1] Furlong W, Rae C, Greenberg M L, et al. Surveillance and survival among adolescents and young adults with cancer in Ontario, Canada[J]. Int J Cancer,2012,131(11):2660-2667.
[2] Schmidt R, Richter D, Sender A, et al. Motivations for having children after cancer-a systematic review of the literature[J]. Eur J Cancer Care:(Engl),2016,25(1):6-17.
[3] Morgan S, Anderson R A, Gourley C, et al. How do chemotherapeutic agents damage the ovary?[J]. Hum Reprod Update,2012,18(5):525-535.
[4] Chemaitilly W, Li Z, Krasin M J, et al. Premature ovarian insufficiency in childhood cancer survivors: A Report from the St. Jude Lifetime Cohort[J]. J Clin Endocrinol Metab,2017, Epub ahead of print.
[5] Meirow D, Biederman H, Anderson R A, et al. Toxicity of chemotherapy and radiation on female reproduction[J]. Clin Obstet Gynecol,2010,53(4):727-739.
[6] Meirow D. Reproduction post-chemotherapy in young cancer patients[J]. Mol Cell Endocrinol,2000,169(1-2):123-131.
[7] Codacci-Pisanelli G, Del P L, Del G M, et al. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients[J]. Crit Rev Oncol Hematol,2017,113:90-96.
[8] Swerdlow A J, Cooke R, Bates A, et al. Risk of premature menopause after treatment for Hodgkin's lymphoma[J]. J Natl Cancer Inst,2014,106(9):pii.
[9] Sullivan S D, Sarrel P M, Nelson L M. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause[J]. Fertil Steril,2016,106(7):1588-1599.
[10] De Vos M, Smitz J, Woodruff T K. Fertility preservation in women with cancer[J]. Lancet,2014,384(9950):1302-1310.
[11] Glujovsky D, Riestra B, Sueldo C, et al. Vitrification versus slow freezing for women undergoing oocyte cryopreservation[J]. Cochrane Database Syst Rev,2014(9):D10047.
[12] Druckenmiller S, Goldman K N, Labella P A, et al. Successful oocyte cryopreservation in reproductive-aged cancer survivors[J]. Obstet Gynecol,2016,127(3):474-480.
[13] Yu K D, Huang S, Zhang J X, et al. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis[J]. BMC Cancer,2013,13:240.
[14] Oktay K, Turan V, Bedoschi G, et al. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer[J]. J Clin Oncol,2015,33(22):2424-2429.
[15] Gremeau A S, Andreadis N, Fatum M, et al. In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles[J]. Fertil Steril,2012,98(2):355-360.
[16] 潘宁宁,马彩虹. 女性生育力保存与肿瘤生殖学[J]. 中国妇产科临床杂志,2015,16(6):481-482.
[17] Roque M, Lattes K, Serra S, et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis[J]. Fertil Steril,2013,99(1):156-162.
[18] Loren A W, Mangu P B, Beck L N, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update[J]. J Clin Oncol,2013,31(19):2500-2510.
[19] Roy T K, Brandi S, Tappe N M, et al. Embryo vitrification using a novel semi-automated closed system yields in vitro outcomes equivalent to the manual Cryotop method[J]. Hum Reprod,2014,29(11):2431-2438.
[20] Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation[J]. Fertil Steril,2013,99(6):1496-1502.
[21] Hovatta O, Silye R, Krausz T, et al. Cryopreservation of human ovarian tissue using dimethylsulphoxide and propanediol-sucrose as cryoprotectants[J]. Hum Reprod,1996,11(6):1268-1272.
[22] Donnez J, Dolmans M M, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue[J]. Lancet,2004,364(9443):1405-1410.
[23] Jensen A K, Macklon K T, Fedder J, et al. 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children[J]. J Assist Reprod Genet,2017,34(3):325-336.
[24] Donnez J, Dolmans M M, Pellicer A, et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation[J]. Fertil Steril,2013,99(6):1503-1513.
[25] Lambertini M, Del M L, Pescio M C, et al. Cancer and fertility preservation: international recommendations from an expert meeting[J]. BMC Med,2016,14:1.
[26] Wallace W H, Smith A G, Kelsey T W, et al. Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation[J]. Lancet Oncol,2014,15(10):1129-1136.
[27] Donnez J, Dolmans M M. Fertility preservation in women[J]. Nat Rev Endocrinol,2013,9(12):735-749.
[28] Dolmans M M, Jadoul P, Gilliaux S, et al. A review of 15 years of ovarian tissue bank activities[J]. J Assist Reprod Genet,2013,30(3):305-314.
[29] Dolmans M M, Marinescu C, Saussoy P, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe[J]. Blood,2010,116(16):2908-2914.
[30] Greve T, Clasen-Linde E, Andersen M T, et al. Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells[J]. Blood,2012,120(22):4311-4316.
[31] Bockstaele L, Tsepelidis S, Dechene J, et al. Safety of ovarian tissue autotransplantation for cancer patients[J]. Obstet Gynecol Int,2012,2012:495142.
[32] Dolmans M M, Luyckx V, Donnez J, et al. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue[J]. Fertil Steril,2013,99(6):1514-1522.
[33] Fadini R, Dal Canto M, Mignini R M, et al. Embryo transfer following in vitro maturation and cryopreservation of oocytes recovered from antral follicles during conservative surgery for ovarian cancer[J]. J Assist Reprod Genet,2012,29(8):779-781.
[34] Telfer E E, Zelinski M B. Ovarian follicle culture: advances and challenges for human and nonhuman primates[J]. Fertil Steril,2013,99(6):1523-1533.
[35] Lonergan P, Fair T. Maturation of oocytes in vitro[J]. Annu Rev Anim Biosci,2016,4:255-268.
[36] Xiao S, Zhang J, Romero M M, et al. In vitro follicle growth supports human oocyte meiotic maturation[J]. Sci Rep,2015,5:17323.
[37] 覃颖,李慕军. 卵巢组织玻璃化冷冻保存和移植的研究进展[J]. 中国组织工程研究,2012,16(18):3411-3416.
[38] Gosden R G, Yin H, Bodine R J, et al. Character, distribution and biological implications of ice crystallization in cryopreserved rabbit ovarian tissue revealed by cryo-scanning electron microscopy[J]. Hum Reprod,2010,25(2):470-478.
[39] Klocke S, Bundgen N, Koster F, et al. Slow-freezing versus vitrification for human ovarian tissue cryopreservation[J]. Arch Gynecol Obstet,2015,291(2):419-426.
[40] Ting A Y, Yeoman R R, Lawson M S, et al. In vitro development of secondary follicles from cryopreserved rhesus macaque ovarian tissue after slow-rate freeze or vitrification[J]. Hum Reprod,2011,26(9):2461-2472.
[41] Herraiz S, Novella-Maestre E, Rodriguez B, et al. Improving ovarian tissue cryopreservation for oncologic patients: slow freezing versus vitrification, effect of different procedures and devices[J]. Fertil Steril,2014,101(3):775-784.
[42] Sanfilippo S, Canis M, Smitz J, et al. Vitrification of human ovarian tissue: a practical and relevant alternative to slow freezing[J]. Reprod Biol Endocrinol,2015,13:67.
[43] Amorim C A, Curaba M, Van Langendonckt A, et al. Vitrification as an alternative means of cryopreserving ovarian tissue[J]. Reprod Biomed Online,2011,23(2):160-186.
[44] Rodriguez-Wallberg K A, Oktay K. Recent advances in oocyte and ovarian tissue cryopreservation and transplantation[J]. Best Pract Res Clin Obstet Gynaecol,2012,26(3):391-405.
[45] Practice Committee of American Society for Reproductive Medicine. Ovarian tissue cryopreservation: a committee opinion[J]. Fertil Steril,2014,101(5):1237-1243.
[46] Kim S S. Assessment of long term endocrine function after transplantation of frozen-thawed human ovarian tissue to the heterotopic site: 10 year longitudinal follow-up study[J]. J Assist Reprod Genet,2012,29(6):489-493.
[47] Donnez J, Dolmans M M. Transplantation of ovarian tissue[J]. Best Pract Res Clin Obstet Gynaecol,2014,28(8):1188-1197.
[48] Jadoul P, Guilmain A, Squifflet J, et al. Efficacy of ovarian tissue cryopreservation for fertility preservation: lessons learned from 545 cases[J]. Hum Reprod,2017,32(5):1046-1054.
[49] Van der Ven H, Liebenthron J, Beckmann M, et al. Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates[J]. Hum Reprod,2016,31(9):2031-2041.
[50] Donnez J, Silber S, Andersen C Y, et al. Children born after autotransplantation of cryopreserved ovarian tissue. A review of 13 live births[J]. Ann Med,2011,43(6):437-450.
[51] Bildik G, Akin N, Senbabaoglu F, et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro[J]. Hum Reprod,2015,30(12):2912-2925.
[52] Turner N H, Partridge A, Sanna G, et al. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain[J]. Ann Oncol,2013,24(9):2224-2235.
[53] Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies[J]. Ann Oncol,2015,26(12):2408-2419.
[54] Donnez J, Dolmans M M. Ovarian tissue freezing: current status[J]. Curr Opin Obstet Gynecol,2015,27(3):222-230.